This design provided a modest breadth of coverage of all coding exons for the targeted genes, namely 29% for CFTR, 15% for PAH, 12% for SERPINA1, and 22% in the case of GJB2. This evidence concerns the gene GJB2 and pulmonary arterial hypertension.